*Trypanosoma cruzi* is the protozoan parasite that causes Chagas disease, responsible for approximately 11 million infections throughout Latin America (CDC 2007). Chagasic heart disease and gastrointestinal mega-syndromes usually occur after decades of chronic asymptomatic *T. cruzi* infection, initiated by either mucosal or systemic routes of vector-borne transmission ([@B14], [@B08], WHO 2010). Infective insect-derived metacyclic trypomastigotes (IMT) are excreted onto the surface of mammalian hosts by infected triatomine bugs, initiating infection of open wounds or mucosal tissues. Contaminative cutaneous \[e.g., through the triatomine bite site (TBS)\]), as well as conjunctival and oral routes of IMT infection are common ( [@B05]). Because of the long delay between initial *T. cruzi* infection and the development of chagasic pathology, in most human cases the actual route of initial infection cannot be determined. Therefore, the relative proportions of infections due to cutaneous, conjunctival and oral routes of transmission are not known.

We previously developed mouse models of both conjunctival and oral *T. cruzi* transmission and determined that the infectious dose establishing infection in 50% (ID ~50~ ) of the animals challenged was approximately 5-20 IMT ([@B12], [@B07]). We further identified gastric epithelial invasion as the anatomical route of infection after oral IMT challenge ([@B10]). Gastric infection resulted in no obvious external signs of infection in the mouse model, suggesting that if gastric infection is also the anatomical route of infection after oral challenge in humans, this route of transmission is likely to be underestimated compared with cutaneous and conjunctival infections which lead to easily visible local cutaneous and periorbital chagomas, respectively. In the current work, we have directly compared the relative ID ~50~ of oral and cutaneous *T. cruzi* challenges simulating natural vector-borne infection through the TBS.

All animal studies were performed in Association for Assessment and Accreditation of Laboratory Animal Care International accredited facilities \[National Institute of Health Assurance (A3225-01)\].

The Tulahuén strain of *T. cruzi* and BALB/c mice (Harlan Sprague-Dawley Inc, Indianapolis, USA) were used in these experiments. IMT were prepared by allowing *T. cruzi* infected triatomine bugs (triatomines, *Dipetalogaster maximus* ) to feed on anesthetised mice. Engorged insects were then incubated in glass vials for 3-5 h, excreta pooled and IMT concentration determined by direct haemocytometer count. Unanesthetised mice were challenged orally with IMT atraumatically by placing 10-30 µL of IMT infected triatomine excreta inside the oropharynx with a P20 pipet as previously described ([@B12], [@B10], [@B13], [@B09]). For contaminative cutaneous challenges, the posterior necks of mice were shaved with an electric razor the day before challenge. Immediately before contaminative cutaneous challenge, mice were anesthetised by intraperitoneal injection of ketamine (60 mg/kg) and xylazine (5 mg/kg). A single puncture mark was placed through the full thickness of the skin with a tuberculin syringe needle and then 10-30 µL of infected triatomine excreta was placed directly over the puncture wound. In some experiments, uninfected triatomine insects were placed onto the shaved area, allowed to feed for 10 min, removed and then infected triatomine excreta placed directly over the feeding puncture wound. Mice remained anesthetised for at least several minutes after placement of infected triatomine excreta. Infection nine, 14 or 30 days post-challenge was identified by real-time polymerase chain reaction (RT-PCR) with DNA from local gastric and cutaneous tissues, as well as by recovery of viable tissue parasites from draining lymph nodes, splenic tissues and blood samples as described below.

Tissue DNA samples were studied nine-30 days after IMT challenges. Mouse stomachs were removed from mice orally challenged with IMT by cutting oesophageal and pyloric attachments. These organs were opened along the greater curvature and flushed with sterile phosphate buffered saline. Full thickness patches of skin approximately 0.5 cm x 0.5 cm were removed from the posterior neck of mice previously challenged with the IMT contaminative cutaneous challenge protocol. Gastric and cutaneous tissue DNA samples were purified and *T. cruzi* specific RT-PCR performed as described previously ([@B13]).

Viable tissue parasitism in different challenge groups was investigated after oral and cutaneous IMT challenges as described previously ([@B10]). Briefly, titrations of gastric lymph node cells, cervical lymph node cells and spleen cells harvested nine-30 days after IMT challenge were incubated at 26 ^°^ C for two months in 96 well microtitre plates with 200 µL of liver digested-neutralised tryptose broth (LDNT)+ ([@B02], [@B11]). Every two weeks wells were inspected by inverted light microscopy for evidence of *T. cruzi* outgrowth.

Heparinised blood (250 µL) from individual mice was collected using aseptic technique and used to inoculate 5 mL of LDNT+ medium. These cultures were incubated for two months at 26°C and examined for outgrowth of *T. cruzi* epimastigotes. *T. cruzi* -specific IgG ELISAs were conducted on serum samples collected 30 days post-IMT challenge as previously described (Eickoff et al. 2011).

Groups of BALB/c mice were challenged orally and cutaneously with 50, 500 and 5,000 IMT in several experiments. Total DNA was extracted from tissues at the predicted sites of cutaneous or mucosal parasite entry from individual mice on days 9 and 14 post-challenge. DNA was extracted from skin at the site where IMT were deposited over the tuberculin syringe puncture mark. DNA was extracted from gastric tissue after oral challenges which we previously identified as the anatomical site of initial mucosal infection after oral IMT challenge ([@B10]). These samples were analysed for the presence of *T. cruzi* DNA by RT-PCR as previously described ([@B13]). Samples purified from cutaneous and gastric tissues did not have inhibitory effects on PCR amplification of purified total *T. cruzi* DNA (data not shown). In addition, we harvested draining cervical lymph node cells (from cutaneously challenged mice), gastric lymph node cells (from orally challenged mice) and spleen cells (from all mice) and quantified viable parasites recoverable from all of these tissues as described previously ([@B10]). Splenic, gastric lymph node and cervical lymph node cells mixed with parasites and plated in our viable tissue culture assays performed as described previously allowed detection of as few as 1-10 blood form trypomastigotes (BFT) (data not shown). As a third method for identifying parasite infection we performed haemocultures on all mice. In-house studies showed that blood spiked with a single BFT reliably resulted in a positive haemoculture test (data not shown). *T. cruzi* -specific IgG ELISAs were conducted with serum samples from challenged mice. [Table I](#t01){ref-type="table"} shows the results of three separate experiments comparing oral vs. cutaneous *T. cruzi* challenges. In the first two experiments, all mice challenged orally with 50-5,000 IMT had evidence of successful infection with *T. cruzi* . In contrast with these results, most mice challenged by our contaminative cutaneous route using a tuberculin syringe puncture mark simulating the TBS did not become infected with *T. cruzi* . In fact, in only one of three experiments did mice reliably become infected after cutaneous challenge and only in the highest dose group (5,000 IMT). To be labelled as negative (uninfected), all assays had to show negative results. To be labelled as positive (infected), at least one assay had to be positive. Parasite outgrowth assay results (quantitative parasite outgrowth cultures and haemocultures) matched RT-PCR results and *T. cruzi* -specific serum IgG ELISA results in 78% and 88% of cases, respectively.

TABLE I*Trypanosoma cruzi* infection after insect-derived metacyclic trypomastigote (IMT) oral and cutaneous contaminative challenges*T. cruzi* challengeExperiment 1 n/nExperiment 2 n/nExperiment 3 n/n50 IMT PO2/22/21/3500 IMT PO1/12/23/35,000 IMT PO2/22/22/350 IMT cut (NP)0/20/20/3500 IMT cut (NP)0/20/21/35,000 IMT cut (NP)0/32/21/350 IMT cut (TBS)NDND0/3500 IMT cut (TBS)NDND0/35,000 IMT cut (TBS)NDND0/3[^1]

[Table II](#t02){ref-type="table"} demonstrates significant differences in infectivity comparing oral versus cutaneous infection at all three doses used (p \< 0.05 by Fisher's exact two-tailed tests). These results agree with our earlier estimations of the ID ~50~ for oral mucosal IMT challenges ([@B12]) and demonstrate that the ID ~50~ for contaminative cutaneous IMT challenge was ≥ 100 times higher.

TABLE IIStatistical significance of oral vs. cutaneous *Trypanosoma cruzi* challenges *T. cruzi* challengePO n/ncut (NP + TBS ) n/np50 IMT5/70/100.003500 IMT6/61/100.0015,000 IMT6/73/110.0498[^2]

It has been shown that components of sand fly saliva can enhance the infectivity of *Leishmania* promastigotes by having vasodilatory and anticoagulant effects ([@B16] ). To rule out the possibility that our needle puncture cutaneous model underestimates the infectivity of *T. cruzi* IMT for contaminative cutaneous challenge, we conducted further experiments placing IMT infected triatomine excreta directly over the TBS immediately after uninfected triatomines had finished feeding on anesthetised mice. The results shown as experiment 3 in [Table I](#t01){ref-type="table"} demonstrate that triatomine saliva did not enhance the cutaneous infectivity of *T. cruzi* IMT.

Contaminative inoculation of IMT into the TBS as well as oral routes of vector-borne *T. cruzi* infection commonly occurs. However, to our knowledge, there has been no direct comparison of the relative infectivities of contaminative cutaneous and oral *T. cruzi* challenges. Our data indicate that *T. cruzi* IMT more efficiently infect through mucosal surfaces than through breaks in the skin. Multiple reports demonstrate that the oral ingestion of *T. cruzi* IMT can lead to human infection and in some cases outbreaks of *T. cruzi* infection linked to oral transmission have been characterised by high lethality (Benchimol Barbosa 2006, [@B15]). In addition, *T. cruzi* is an enzootic infection with many species of mammals serving as reservoirs in nature. Most of this salvatic transmission is thought to be acquired by mammals eating *T. cruzi*-infected triatomine bugs. Therefore the oral route of *T. cruzi* infection is clearly important and may be overall the most important route of vector borne transmission.

We do not believe that the lower ID ~50~ seen for contaminative cutaneous IMT infection is due to a relative inability of *T. cruzi* parasites to replicate within cutaneous tissues. *T. cruzi* IMT can infect and replicate within virtually all nucleated mammalian cells. *T. cruzi* IMT cannot penetrate intact stratum corneum. With the TBS being less than 1 mm in diameter, the probability of IMT present in triatomine excreta gaining access to this small break in the stratum corneum is small. In contrast, both gastric and conjunctival surfaces provide large areas through which IMT can infect.

Our results demonstrate that *T. cruzi* IMT are significantly more infectious after mucosal compared with cutaneous routes of exposure. We recognise that variations in infectivity may occur with different parasite strains expressing distinct parasite proteins including surface glycoproteins such as gp30/gp82 ([@B04]). Further research utilising different parasite/mouse strain combinations is needed to address this question. Regardless, our results indicate that future preventative environmental and vaccination approaches should focus on both the prevention of mucosal and systemic *T. cruzi* infection.

[^1]: shown are the number of mice infected/number challenged (from 3 separate experiments). To be considered uninfected, mice had to have negative *T. cruzi* specific polymerase chain reaction (PCR), viable *T. cruzi* outgrowth assays and *T. cruzi*-specific IgG ELISA. Parasite outgrowth assay results (quantitative parasite outgrowth cultures and haemocultures) matched real-time PCR results and *T. cruzi*-specific serum IgG ELISA results in 78% and 88% of cases, respectively. Mice were harvested nine days after challenge in experiment 1, 14 days after challenge in experiment 2 and 30 days after challenge in experiment 3. cut: cutaneous; ND: not done; NP: needle prick; PO: perorally; TBS: triatomine bite site.

[^2]: the number of mice infected/number challenged and Fisher's exact two-tailed p-values are shown. To be considered uninfected, mice had to have negative *T. cruzi* specific polymerase chain reaction (PCR), viable *T. cruzi* outgrowth assays, and *T. cruzi* -specific IgG ELISA. Parasite outgrowth assay results (quantitative parasite outgrowth cultures and haemocultures) matched real-time PCR results and *T. cruzi* -specific serum IgG ELISA results in 78% and 88% of cases, respectively. Mice were harvested nine-30 days after insect-derived metacyclic trypomastigote (IMT) challenge. cut: cutaneous; NP: needle prick; PO: perorally; TBS: triatomine bite site.
